NASDAQ:CBIO - Catalyst Biosciences Stock Price, Forecast & News

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Catalyst Biosciences's stock reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

Catalyst Biosciences Inc (NASDAQ:CBIO) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.01. View Catalyst Biosciences' Earnings History.

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Catalyst Biosciences.

1 equities research analysts have issued 1-year price objectives for Catalyst Biosciences' stock. Their forecasts range from $25.00 to $25.00. On average, they anticipate Catalyst Biosciences' share price to reach $25.00 in the next year. This suggests a possible upside of 336.3% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.

News coverage about CBIO stock has been trending somewhat negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catalyst Biosciences earned a news impact score of -1.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Catalyst Biosciences.

Catalyst Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 602,800 shares, an increase of 7.4% from the January 15th total of 561,100 shares. Based on an average daily trading volume, of 485,100 shares, the days-to-cover ratio is currently 1.2 days. Approximately 5.5% of the shares of the stock are sold short. View Catalyst Biosciences' Current Options Chain.

Some companies that are related to Catalyst Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Celsion (CLSN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), NovaBay Pharmaceuticals (NBY), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Melinta Therapeutics (MLNT) and Nabriva Therapeutics (NBRV).

Catalyst Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Marshall Wace LLP (1.04%), Credit Suisse AG (0.84%), Renaissance Technologies LLC (0.41%), Goldman Sachs Group Inc. (0.29%), Private Advisors LLC (0.20%) and Ellington Management Group LLC (0.16%). Company insiders that own Catalyst Biosciences stock include Howard Levy, James E Flynn and John P Richard. View Institutional Ownership Trends for Catalyst Biosciences.

CBIO stock was sold by a variety of institutional investors in the last quarter, including Private Advisors LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Catalyst Biosciences.

CBIO stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Credit Suisse AG, Renaissance Technologies LLC, Ellington Management Group LLC, Marshall Wace North America L.P. and UBS Group AG. View Insider Buying and Selling for Catalyst Biosciences.

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBIO stock can currently be purchased for approximately $5.73.

Catalyst Biosciences has a market capitalization of $69.22 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.View Additional Information About Catalyst Biosciences.

The official website for Catalyst Biosciences is http://www.catalystbiosciences.com/.

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]